摘要
目的研究吡格列酮对2型糖尿病患者血脂的影响。方法选取门诊初诊2型糖尿病患者78例,随机分为治疗组39例,对照组39例。治疗组给予吡格列酮每日30mg;对照组给予罗格列酮每日8mg,共观察24周。结果于24周时,治疗组和对照组空腹血糖、餐后2h血糖均较治疗前明显降低(P<0.01),2组间的降低程度没有显著性差异(P>0.05)。治疗组血三酰甘油和总胆固醇水平较治疗前明显降低(P<0.01),但对照组无明显变化(P>0.05)。2组高密度脂蛋白胆固醇水平均比治疗前明显升高(P<0.05,P<0.01),且治疗组升高幅度大于对照组(P<0.05)。结论吡格列酮对2型糖尿病患者血脂的影响明显优于罗格列酮。
Objective To observe the effect of pioglitazone on blood lipids in patients with type 2 diabetes. Methods Seventy-eight outpatients with hyperglyeaemia and hyperlipidemia which were fist checked out were divided into two groups randomly ： pioglitazone therapy group and control group from 2006 to 2008. Patients in group A were received 24 - week therapy with pioghtazone ,30rag daily. The control group were received 24 - week therapy with rosiglitazone ,Stag daily. Results 24 weeks later, the levels of FPG and 2hPG decreased significantly in both groups （P 〈 0.01 ）, and the decreasing degree has no statistical difference between two groups （ P 〉 0.05 ）. The level of TC and TG decreased significantly in group A （ P 〈 0. 01 ）, but no significant change in group B （ P 〉 0.05 ）. The level of HDLC increased significantly inboth groups （ P 〈 0. 05, P 〈0.01 respectively）, but the increasing degree is higher in group A than group B. Conclusion Pioglitazone has better effects of improving blood lipids in patients with type 2 diabetes.
出处
《临床合理用药杂志》
2009年第2期9-10,共2页
Chinese Journal of Clinical Rational Drug Use
